Brokerages expect that MEDNAX Inc (NYSE:MD) will report $0.84 earnings per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for MEDNAX’s earnings. The highest EPS estimate is $0.88 and the lowest is $0.75. MEDNAX reported earnings per share of $0.75 during the same quarter last year, which indicates a positive year over year growth rate of 12%. The business is scheduled to report its next earnings report on Thursday, April 19th.
On average, analysts expect that MEDNAX will report full year earnings of $4.22 per share for the current year, with EPS estimates ranging from $4.02 to $4.30. For the next fiscal year, analysts anticipate that the business will report earnings of $4.47 per share, with EPS estimates ranging from $4.32 to $4.65. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow MEDNAX.
MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The company had revenue of $910.82 million during the quarter, compared to analyst estimates of $884.55 million. During the same quarter in the previous year, the firm earned $1.00 earnings per share. MEDNAX’s revenue was up 9.6% on a year-over-year basis.
Several analysts have issued reports on the company. Mizuho reaffirmed a “neutral” rating and issued a $53.00 target price (up previously from $49.00) on shares of MEDNAX in a research note on Friday, February 9th. Robert W. Baird upped their target price on MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Stephens set a $62.00 target price on MEDNAX and gave the stock a “buy” rating in a research note on Thursday, February 8th. Jefferies Group set a $50.00 target price on MEDNAX and gave the stock a “hold” rating in a research note on Tuesday, February 6th. Finally, JPMorgan Chase & Co. upped their target price on MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, February 12th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $54.92.
Shares of MEDNAX (MD) traded down $0.11 on Thursday, reaching $57.51. The company’s stock had a trading volume of 634,555 shares, compared to its average volume of 981,301. The stock has a market capitalization of $5,390.00, a price-to-earnings ratio of 16.67, a P/E/G ratio of 1.40 and a beta of 0.31. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.18 and a current ratio of 1.18. MEDNAX has a 1-year low of $40.56 and a 1-year high of $72.13.
In other news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.40% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Fuller & Thaler Asset Management Inc. bought a new position in shares of MEDNAX during the third quarter valued at approximately $103,000. Delta Capital Management LLC bought a new position in shares of MEDNAX during the fourth quarter valued at approximately $227,000. Denali Advisors LLC bought a new position in shares of MEDNAX during the third quarter valued at approximately $185,000. Brown Advisory Inc. bought a new position in shares of MEDNAX during the fourth quarter valued at approximately $231,000. Finally, YHB Investment Advisors Inc. bought a new position in shares of MEDNAX during the fourth quarter valued at approximately $235,000. Institutional investors own 95.12% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/22/mednax-inc-md-expected-to-announce-earnings-of-0-84-per-share.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Get a free copy of the Zacks research report on MEDNAX (MD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.